<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052818</url>
  </required_header>
  <id_info>
    <org_study_id>INCAN/OfCA204/SO151/CB451/09</org_study_id>
    <secondary_id>87453</secondary_id>
    <nct_id>NCT01052818</nct_id>
  </id_info>
  <brief_title>Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Cancerología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Cancerología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the association between the number of circulating
      tumor cells and response to treatment in non small-cell lung cancer patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In spite of technological advantages in diagnosis and treatment, lung cancer remains one of
      the most deadly malignant neoplasias. Moreover, there are no markers for monitoring response
      to treatment. The objective of the study is to associate the number of circulating tumor
      cells (CTC) before and after treatment and correlate it with tumor response rate,
      progression-free survival and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate, progression-free survival and over-all survival</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of CTCs</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Circulating Tumor Cells</condition>
  <arm_group>
    <arm_group_label>Stage IV NSCLC</arm_group_label>
    <description>Stage IV non small-cell lung cancer patients will be recruited for this protocol</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples are collected were the cell pellet are collected from
      centrifugation, lysed by TRIzol method to get RNA. The RNA is retrotranscribed to cDNA in
      order to quantify cytokeratin (CK) 19, 18 and carcinoembrionic antigen which are markers of
      epithelial cells presumambly coming form the tumor.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced non small-cell lung cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologic diagnosis of non small-cell lung cancer

          -  Clinical stage IV

          -  ECOG functional status 0 or 1

          -  No renal function alteration (GFR &gt;50%)

          -  No hepatic function alteration (ALT and AST less than 2 times its normal value)

          -  Leucocytes more than 2,000/mcl

          -  Hemoglobin more than 10mg/dL

          -  Platelets more than 100,000/mcl

        Exclusion Criteria:

        Non-advanced disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Arrieta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Counsil of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oscar Arrieta, MD</last_name>
    <phone>(0155)56280400</phone>
    <phone_ext>832</phone_ext>
    <email>ogar@servidor.unam.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Cancerologia</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Arrieta, MD</last_name>
      <phone>(0155)56280400</phone>
      <phone_ext>832</phone_ext>
      <email>ogar@servidor.unam.mx</email>
    </contact>
    <investigator>
      <last_name>Oscar Arrieta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2010</study_first_submitted>
  <study_first_submitted_qc>January 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>January 18, 2010</last_update_submitted>
  <last_update_submitted_qc>January 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Oscar Arrieta Rodriguez</name_title>
    <organization>CONACyT</organization>
  </responsible_party>
  <keyword>Non small-cell lung cancer</keyword>
  <keyword>Circulating tumor cells</keyword>
  <keyword>Carcinoembryonic antigen</keyword>
  <keyword>Cytokeratin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

